About the Authors

Robert C. Jackson

Affiliation Pharmacometrics Ltd, Cambridge, United Kingdom

Giovanni Y. Di Veroli

Giovanni.DiVeroli@astrazeneca.com

Affiliations Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, QCP, Early Clinical Development—Innovative Medicines, AstraZeneca, Cambridge, United Kingdom

Siang-Boon Koh

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

Ian Goldlust

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

Frances M. Richards

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

Duncan I. Jodrell

Affiliation Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

Competing Interests

I have read the journal's policy and the authors of this manuscript have the following competing interests: RCJ is a paid employee of Pharmacometrics Ltd. GYD is a paid employee of AstraZeneca.

Author Contributions

Conceptualization: RCJ GYD. Data curation: RCJ. Formal analysis: RCJ GYD. Funding acquisition: DIJ. Investigation: SBK. Methodology: RCJ. Project administration: GYD. Resources: FMR. Software: RCJ. Supervision: GYD. Validation: FMR GYD. Visualization: RCJ FMR GYD IG. Writing – original draft: GYD RCJ. Writing – review & editing: RCJ FMR GYD.